Sedat Karademir

Prof. Dr. Sedat Karademir

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
TUTarkan Unek
Tarkan Unek
SKSedat Karademir
Sedat Karademir
NANaciye Cigdem Arslan
Naciye Cigdem Arslan
TETufan Egeli
Tufan Egeli
GAGulsen Atasoy
Gulsen Atasoy
IAIbrahim Astarcioglu
Ibrahim Astarcioglu
To assess the validity of the Milan and University of California San Francisco (UCSF) criteria and examine the long-term outcome of orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC) in a single-center study. This study is a retrospective review of prospectively collected data. Between 1998 and 2009, 56 of 356 OLTs were performed in patients with HCC. Based on pathological examination of liver explants, patients were retrospectively categorized into 3 grou-ps: Milan + (n = 34), Milan -/UCSF + (n = 7) and UCSF - (n = 14). Median follow-up period was 39.5 (1-124) mo. The 5-year overall survival rates in the Milan +, Milan -/UCSF + and UCSF-groups were 87.7%, 53.6% and 33.3%, respectively (P < 0.000). Within these groups, tumor recurrence was determined in 5.8%, 14.3% and 40% of patients, respectively (P < 0.011). Additionally, the presence of microvascular invasion within the explanted liver had a negative effect on the 5-year disease free survival (74.7% vs. 46.7%, P < 0.044). The Milan criteria are reliable in the selection of suitable candidates for OLT for the treatment of HCC. For cases of OLT involving living donors, the UCSF criteria may be applied.

10 September 2018 in Hepatoma Research
Verified
Journal Article
Open access
SKSedat Karademir
Sedat Karademir
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.

1 January 2024 in Hepatology Forum
Verified
Journal Article
Open access
MAMesut Akarsu
Mesut Akarsu
SDSüleyman DOLU
Süleyman DOLU
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
SYSezai Yilmaz
Sezai Yilmaz
MAMurat Akyildiz
Murat Akyildiz
RIRamazan Idilman
Ramazan Idilman
Background and Aim: This study aimed to identify the indications for liv-er transplantation (LT) based on underlying etiology and to characterize the patients who underwent LT. Materials and Methods: We conducted a multicenter crosssectional ob-servational study across 11 tertiary centers in Turkiye from 2010 to 2020. The study included 5,080 adult patients. Results: The mean age of patients was 50.3±15.2 years, with a predominance of female patients (70%). Chronic viral hepatitis (46%) was the leading etiological factor, with Hepatitis B virus infection at 35%, followed by cryptogenic cirrhosis (24%), Hepatitis C virus infection (8%), and al-cohol-related liver disease (ALD) (6%). Post-2015, there was a significant increase in both the number of liver transplants and the proportion of living donor liver transplants (p

1 April 2007
Verified
Journal Article
Closed access
KAKoray Atila
Koray Atila
ACAhmet Coker
Ahmet Coker
DUDeniz Uçar
Deniz Uçar
SKSedat Karademir
Sedat Karademir
OSOzgül Sağol
Ozgül Sağol
IAIbrahim Astarcioğlu
Ibrahim Astarcioğlu

15 September 2021 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MAMesut Akarsu
Mesut Akarsu
SÖSoner Önem
Soner Önem
ITIlker Turan
Ilker Turan
GAGupse Adali
Gupse Adali
MAMeral Akdogan
Meral Akdogan
ZKZeki Karasu
Zeki Karasu
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation.

1 May 2004 in Transplant International
Verified
Journal Article
Closed access
KAKoray Atila
Koray Atila
IAIbrahim Astarcioglu
Ibrahim Astarcioglu
SKSedat Karademir
Sedat Karademir
Disturbed microcirculation caused by fat accumulation in hepatocytes has been implicated in poor graft preservation and reperfusion. The aim of this study was to investigate the effect of vascular bed expansion (VBE) during cold preservation in graft survival Moderate liver steatosis in male Wistar rats (240-280 g) was induced by choline-deficient diet. Normal, steatotic or VBE-pretreated steatotic grafts were transplanted after 1 h or 9 h of cold preservation. Graft viability was determined by 7-day survival, serum liver enzymes, plasma tumour necrosis factor (TNF)-alpha, interleukin (IL)-6, and malondialdehyde (MDA) levels. Post-reperfusion bile flow and liver histology were also examined. After 9 h of preservation, VBE-pretreated steatotic liver grafts were associated with significantly reduced serum liver enzyme, plasma TNF-alpha, IL-6, and MDA levels, as well as increased bile flow and higher survival rates compared with untreated ones. The present study shows that VBE protects fatty liver grafts from subsequent long-term cold preservation and reperfusion injury in a rat liver transplantation model.